Stocks · Healthcare · Biotechnology
X4 Pharmaceuticals, Inc. XFOR
$2.83 +0.00% Close, Oct 2, 2026 · NASDAQ · Market cap $266.9M
Expensive vs sector
Next earnings report: Nov 4, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Operating margin narrowed to -554.7% from -323.1% a year earlier.
- The diluted share count rose 1604.4% in a year.
- Revenue over the last four quarters was $15.8M, down 51.6% from a year earlier, accelerating from -71.3% a quarter earlier.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 11%
- Revenue growth accelerationTop 9%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 35%
- Gross marginTop 29%
- Operating marginBottom 16%
- Accruals (lower is better)Bottom 27%
- Interest coverBottom 33%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 18%
- Free-cash-flow yieldBottom 15%
- EBITDA / enterprise valueBottom 11%
- Sales / enterprise valueBottom 32%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 43%
- 6-month returnBottom 14%
- 1-year return vs S&P 500Bottom 28%
- Distance from 52-week highBottom 39%
- Trend checklist (0–4)Bottom 14%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 20%
- Consecutive EPS beatsTop 12%
- Share of analysts rating BuyTop 23%
- Upside to consensus price targetTop 10%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 35%
- Maximum drawdown, 3 yearsBottom 3%
- Beta vs S&P 500 (lower is better)Bottom 46%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | -71.3% | -51.6% | ↑ |
| Gross margin | 81.4% | 81.2% | ↓ |
| Operating margin | -323.1% | -554.7% | ↓ |
| FCF margin | -343.0% | -528.4% | ↓ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | -51.6% | -71.3% | ↑ | Bottom 11% |
| Gross margin | 81.2% | 81.4% | ↓ | Top 29% |
| Operating margin | -554.7% | -323.1% | ↓ | Bottom 16% |
| Net margin | -568.8% | -311.1% | ↓ | — |
| Free-cash-flow margin | -528.4% | -343.0% | ↓ | — |
| Return on invested capital | -37.5% | — | Bottom 35% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -2.5%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 53.8%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +61.4 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
- Interest cover (operating income / interest)How many times operating profit covers interest.
- -10.1×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -87.30%
- Shareholder yield
- -87.30%
- Share count change, 1 year
- +1604.4%
- Share count change, 3-year CAGR
- +182.2%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 6, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 6
- Beats in the last 8 reports
- 6 of 8
- Average EPS surprise, last 4
- +24.4%
- Average 2-day reaction, last 8
- -6.5%
- Positive 20 days after report
- 3 of 8
Analysts
- Consensus price target
- $11.50
- Target vs current price
- +306.4%
- Analysts with a rating
- 13
- Share rating Buy or Strong Buy
- 92%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 7, 2026 | +26.1% | +11.3% | +2.9% | -3.1% | — |
| May 6, 2026 | +20.0% | +4.3% | +3.3% | -5.5% | -5.2% |
| Mar 17, 2026 | +38.9% | +18.8% | +14.3% | +18.0% | +4.8% |
| Nov 5, 2025 | +12.7% | -10.6% | -11.1% | -18.1% | +0.3% |
| Aug 8, 2025 | +23.4% | +2.1% | +115.1% | +139.7% | +176.7% |
| May 1, 2025 | +101.0% | -13.0% | -24.8% | -18.3% | -50.6% |
| Mar 25, 2025 | -17.6% | -12.1% | -19.9% | -31.2% | -68.1% |
| Nov 13, 2024 | -5.9% | -53.2% | -37.8% | +28.5% | -20.8% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 7, 2026 | -$0.13 | -$0.18 | +26.1% | $8.8M |
| May 6, 2026 | -$0.16 | -$0.20 | +20.0% | $2.7M |
| Mar 17, 2026 | -$0.22 | -$0.36 | +38.9% | $2.6M |
| Nov 5, 2025 | -$0.69 | -$0.79 | +12.7% | $1.8M |
| Aug 8, 2025 | -$3.47 | -$4.53 | +23.4% | $2.0M |
| May 1, 2025 | $0.04 | -$4.13 | +101.0% | $28.8M |
| Mar 25, 2025 | -$6.01 | -$5.11 | -17.6% | $1.4M |
| Nov 13, 2024 | -$5.41 | -$5.11 | -5.9% | $560,000 |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / Sales | 9.41× | — | — | Bottom 32% |
| Free-cash-flow yield | -31.37% | — | — | Bottom 15% |
| Earnings yield | -42.40% | — | — | Bottom 18% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✗ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- -6.7%
- 200-day average slope (20 days)
- -0.9%
- Distance from 50-day average
- -25.7%
- Distance from 200-day average
- -27.5%
- RSI (14)
- 23.2
- Relative volume
- 0.71×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 64.5%
- Volatility vs own 5-year history
- 6th percentile · Low for this stock
- Beta vs S&P 500 (2 years, weekly)
- 1.19
- Correlation with S&P 500
- 0.14
- Current drawdown from 1-year high
- -39.4%
- Maximum drawdown, 3 years
- -96.8%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Mar 22, 2021 | Aug 11, 2025 | -99.5% | 1102 days | Not yet recovered |
| Oct 9, 2020 | Oct 28, 2020 | -26.9% | 13 days | 48 days (Jan 7, 2021) |
| Jan 19, 2021 | Jan 28, 2021 | -12.7% | 7 days | 7 days (Feb 8, 2021) |
| Mar 1, 2021 | Mar 18, 2021 | -12.1% | 13 days | 1 days (Mar 19, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $266.9M
- EPS, diluted (TTM)
- -$1.20
- Revenue (TTM)
- $15.8M
- 52-week range
- $2.75 – $4.83
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $2.6M | $35.1M |
| Gross profit | -$1.9M | $0 | $0 | $1.8M | $28.9M |
| Operating income | -$75.3M | -$87.6M | -$107.5M | -$36.4M | -$86.9M |
| Net income | -$88.7M | -$93.9M | -$101.2M | -$37.5M | -$79.2M |
| EPS (diluted) | -$119.58 | -$45.60 | -$17.07 | -$5.59 | -$1.87 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $560,000 | $1.4M | $28.8M | $2.0M | $1.8M | $2.6M | $2.7M | $8.8M |
| Net income | -$36.7M | -$39.8M | $282,000 | -$25.7M | -$29.8M | -$23.9M | -$20.2M | -$16.2M |
| EPS (diluted) | -$5.48 | -$6.00 | $0.04 | -$3.47 | -$0.69 | -$0.22 | -$0.16 | -$0.13 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$70.9M | -$77.1M | -$96.5M | -$130.9M | -$85.6M |
| Capital expenditure | -$615,000 | -$103,000 | -$60,000 | -$7.3M | -$3.0M |
| Free cash flow | -$71.5M | -$77.2M | -$96.6M | -$138.2M | -$88.6M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $74.2M | $122.6M | $60.0M | $294,000 | $238.5M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $208.0M
- Total assets
- $253.1M
- Total liabilities
- $97.6M
- Total debt
- $77.2M
- Net debt
- -$117.9M
- Shareholders’ equity
- $155.5M
As of Jun 30, 2026 (filed Aug 6, 2026).
Short interest
- Shares sold short
- 8,236,475
- Days to cover
- 7.07
- Change vs previous report
- +14.6%
FINRA short interest, settlement date Sep 15, 2026.
Stock splits
- Apr 28, 2025
- 1-for-30
- Mar 14, 2019
- 1-for-6